# Mammary Gland Microbiota in Benign Breast Diseases

## TL;DR

This review explores how the microbiome in the mammary gland contributes to benign breast diseases, highlighting potential diagnostic and therapeutic opportunities.

## Contribution

The paper provides the first comprehensive synthesis of the role of mammary gland microbiota in benign breast diseases.

## Key findings

- Distinct microbial signatures like Corynebacterium kroppenstedtii and Staphylococcus aureus are associated with specific benign breast conditions.
- Gut microbial profiles in BBD patients show altered abundances of Clostridium, Faecalibacterium, Collinsella, and Alistipes.
- Microbial dysbiosis is identified as a key factor in the pathogenesis of benign breast diseases.

## Abstract

The human microbiome is a critical factor in health and disease. While its association with breast cancer (BC) has been increasingly studied, this review provides a dedicated synthesis of the microbiota’s role in benign breast diseases (BBDs)—a common yet microbiologically overlooked spectrum of conditions. The primary aim of this work is to consolidate the current understanding of the composition, origins, and functional mechanisms of the mammary gland (MG) microbiota specifically in the context of BBD and to evaluate its potential for novel diagnostic and therapeutic targets. We detail the distinct MG microbiota, formed via exogenous (e.g., cutaneous, translocation) and endogenous (e.g., enteromammary, lymphohematogenous) pathways, and its interaction with the host through estrogen metabolism, immunomodulation, and epigenetic modifications. This narrative review reveals unique dysbiotic patterns in BBD, characterized by distinct microbial signatures, such as the enrichment of Corynebacterium kroppenstedtii in granulomatous mastitis and the presence of Staphylococcus aureus in fibroadenomas and lactational mastitis. Furthermore, specific gut microbial profiles are identified in BBD patients, including an increased abundance of genera such as Clostridium and Faecalibacterium, alongside a decrease in Collinsella and Alistipes compared to healthy controls. These specific taxa represent compelling candidates for diagnostic biomarkers. We conclude that microbial dysbiosis is a significant component of BBD pathogenesis. A paradigm shift toward multi-omics approaches and mechanistic studies is now essential to translate these associations into clinical applications. Understanding the BBD-specific microbiome holds the promise of revolutionizing patient care through microbiota-based diagnostics for differentiating benign subtypes and novel, personalized therapeutic strategies aimed at restoring microbial homeostasis.